Export 6 results:
Author [ Title(Desc)] Type Year
Filters: Author is Keefer, Michael C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
C. Schmidt, Smith, C., Barin, B., Bakhtyari, A., Bart, P. - A., Bekker, L. - G., Chomba, E., Clumeck, N., Ho, D., Hoosen, A., Jaoko, W., Kaleebu, P., Karita, E., Keefer, M. C., van Lunzen, J., McMichael, A., Mehendale, S., Peters, B., Ramanathan, V. D., Robinson, A., Rockstroh, J., Vardas, E., Vets, E., Weber, J., Graham, B. S., Than, S., Excler, J. - L., Kochhar, S., Ho, M., Heald, A., and Fast, P. E., “Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.”, Hum Vaccin Immunother, vol. 8, no. 5, pp. 630-8, 2012.
C
P. F. Wright, Mestecky, J., M McElrath, J., Keefer, M. C., Gorse, G. J., Goepfert, P. A., Moldoveanu, Z., Schwartz, D., Spearman, P. W., Habib, R. El, Spring, M. D., Zhu, Y., Smith, C., Flores, J., and Weinhold, K. J., “Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.”, J Infect Dis, vol. 189, no. 7, pp. 1221-31, 2004.
I
B. S. Graham, M McElrath, J., Keefer, M. C., Rybczyk, K., Berger, D., Weinhold, K. J., Ottinger, J., Ferarri, G., Montefiori, D. C., Stablein, D., Smith, C., Ginsberg, R., Eldridge, J., Duerr, A., Fast, P., and Haynes, B. F., “Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.”, PLoS One, vol. 5, no. 8, p. e11995, 2010.
P
S. Vasan, Schlesinger, S. J., Chen, Z., Hurley, A., Lombardo, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Boente-Carrera, M., Schmidt, C., Fang, Q., Huang, Y., Zaharatos, G. J., Gardiner, D. F., Caskey, M., Seamons, L., Ho, M., Dally, L., Smith, C., Cox, J., Gill, D., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., “Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8816, 2010.
S. Vasan, Schlesinger, S. J., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D. K., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., “Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.”, PLoS One, vol. 5, no. 1, p. e8617, 2010.
M. C. Keefer, Gilmour, J., Hayes, P., Gill, D., Kopycinski, J., Cheeseman, H., Cashin-Cox, M., Naarding, M., Clark, L., Fernandez, N., Bunce, C. A., Hay, C. M., Welsh, S., Komaroff, W., Hachaambwa, L., Tarragona-Fiol, T., Sayeed, E., Zachariah, D., Ackland, J., Loughran, K., Barin, B., Cormier, E., Cox, J. H., Fast, P., and Excler, J. - L., “A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.”, PLoS One, vol. 7, no. 8, p. e41936, 2012.